Soy and Lipoproteins in Postmenopausal Women
Primary Purpose
Atherosclerosis, Cardiovascular Diseases, Heart Diseases
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Soy
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Atherosclerosis
Eligibility Criteria
Inclusion criteria postmenopausal women elevated cholesterol
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Intervention
Placebo
Arm Description
dietary supplement soy protein containing isoflavones
dietary supplement casein placebo
Outcomes
Primary Outcome Measures
LDL cholesterol level
LDL cholesterol will be measured in blood in mg/dl
Secondary Outcome Measures
Full Information
NCT ID
NCT00201162
First Posted
September 16, 2005
Last Updated
August 28, 2018
Sponsor
Johns Hopkins University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00201162
Brief Title
Soy and Lipoproteins in Postmenopausal Women
Official Title
Soy and Lipoproteins in Postmenopausal Women
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
September 2001 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To determine the effects of soy on lipids, lipoproteins and lipoprotein subclass in a sample of African-American and white postmenopausal women with low-density lipoprotein (LDL) cholesterol elevations that may increase their lifetime risk for cardiovascular disease but would not qualify for definite pharmacotherapy under current guidelines.
Detailed Description
BACKGROUND:
Cardiovascular disease (CVD) remains the leading cause of mortality and disability in postmenopausal women. Menopause alters serum lipids and lipoproteins to produce a more atherogenic lipid profile that may contribute significantly to the increased risk for the development of CVD over the lifetime of women. Clinical trials have demonstrated a beneficial effect of soy protein containing isoflavones (soy) on plasma lipids and lipoproteins; however, these studies included small numbers of postmenopausal women and virtually none included sufficient African-American women. In addition, no published data existed in 2001 on the impact of soy on atherogenic lipoprotein subclasses in postmenopausal women.
DESIGN NARRATIVE:
The study was a double blind, parallel group, randomized clinical trial. A total of 216 healthy postmenopausal women (50 percent African-American) with LDL cholesterol between 130 mg/dL and 190 mg/dL were enrolled. Following a pre-randomization run-in period on a NCEP Step I diet, women were randomized to receive soy containing isoflavones or casein dietary supplements for 3 months. Major outcome variables were assessed in both groups at baseline and again at 3 months. It was hypothesized that soy supplementation would result in significantly greater reduction in LDL cholesterol, LDL particle concentration, and prevalence of dense LDL particles and improvement in menopausal quality of life compared with placebo and that these effects would be comparable in African-Americans and whites. This was the first study to determine whether a natural plant product could ameliorate the unfavorable changes in known and novel lipid risk factors that are a consequence of menopause in both African-American and white women. The unique transitional outcomes explored in this study added substantially to the limited body of knowledge of the effects of soy. Evaluation of this nutritional alternative to hormone replacement therapy (HRT) that may provide a beneficial effect on lipid risk factors and menopausal symptoms but would be free of the adverse effects on triglycerides, the breast and uterus, and thrombotic events associated with HRT could have significant public health implications for postmenopausal women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Menopause
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
216 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
dietary supplement soy protein containing isoflavones
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
dietary supplement casein placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Soy
Intervention Description
Dietary supplement of isolated soy protein containing isoflavones
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
dietary supplement casein placebo
Primary Outcome Measure Information:
Title
LDL cholesterol level
Description
LDL cholesterol will be measured in blood in mg/dl
Time Frame
3 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
postmenopausal women
elevated cholesterol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerilyn Allen
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Soy and Lipoproteins in Postmenopausal Women
We'll reach out to this number within 24 hrs